Genmab Financial Statements From 2010 to 2025
| GNMSF Stock | USD 222.23 7.07 3.08% |
Check Genmab A/S financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab A/S's main balance sheet or income statement drivers, such as , as well as many indicators such as . Genmab financial statements analysis is a perfect complement when working with Genmab A/S Valuation or Volatility modules.
Genmab |
Genmab AS Company Profit Margin Analysis
Genmab A/S's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genmab A/S Profit Margin | 0.47 % |
Most of Genmab A/S's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Genmab AS has a Profit Margin of 0.4717%. This is 104.21% lower than that of the Healthcare sector and 102.05% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 137.14% lower than that of the firm.
Genmab A/S Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genmab A/S's current stock value. Our valuation model uses many indicators to compare Genmab A/S value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genmab A/S competition to find correlations between indicators driving Genmab A/S's intrinsic value. More Info.Genmab AS is rated # 3 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genmab AS is roughly 2.29 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genmab A/S's earnings, one of the primary drivers of an investment's value.About Genmab A/S Financial Statements
Genmab A/S stakeholders use historical fundamental indicators, such as Genmab A/S's revenue or net income, to determine how well the company is positioned to perform in the future. Although Genmab A/S investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab A/S's assets and liabilities are reflected in the revenues and expenses on Genmab A/S's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out the analysis of Genmab A/S Correlation against competitors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.